Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
ALRPRB's Cash to Debt is ranked lower than
92% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. ALRPRB: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
ALRPRB' s 10-Year Cash to Debt Range
Min: 0.08   Max: N/A
Current: 0.13

Equity to Asset 0.34
ALRPRB's Equity to Asset is ranked lower than
81% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ALRPRB: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
ALRPRB' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.77
Current: 0.34

-0.49
0.77
Interest Coverage 0.47
ALRPRB's Interest Coverage is ranked lower than
99% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3194.09 vs. ALRPRB: 0.47 )
Ranked among companies with meaningful Interest Coverage only.
ALRPRB' s 10-Year Interest Coverage Range
Min: 0.04   Max: 3.6
Current: 0.47

0.04
3.6
F-Score: 5
Z-Score: 0.94
M-Score: -2.51
WACC vs ROIC
10.64%
3.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 3.30
ALRPRB's Operating margin (%) is ranked higher than
56% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. ALRPRB: 3.30 )
Ranked among companies with meaningful Operating margin (%) only.
ALRPRB' s 10-Year Operating margin (%) Range
Min: -92.15   Max: 13.42
Current: 3.3

-92.15
13.42
Net-margin (%) 6.48
ALRPRB's Net-margin (%) is ranked higher than
73% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. ALRPRB: 6.48 )
Ranked among companies with meaningful Net-margin (%) only.
ALRPRB' s 10-Year Net-margin (%) Range
Min: -149.74   Max: 6.61
Current: 6.48

-149.74
6.61
ROE (%) 8.63
ALRPRB's ROE (%) is ranked higher than
71% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.79 vs. ALRPRB: 8.63 )
Ranked among companies with meaningful ROE (%) only.
ALRPRB' s 10-Year ROE (%) Range
Min: -172.73   Max: 10.39
Current: 8.63

-172.73
10.39
ROA (%) 2.56
ALRPRB's ROA (%) is ranked higher than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. ALRPRB: 2.56 )
Ranked among companies with meaningful ROA (%) only.
ALRPRB' s 10-Year ROA (%) Range
Min: -36.19   Max: 3.56
Current: 2.56

-36.19
3.56
ROC (Joel Greenblatt) (%) 8.26
ALRPRB's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.57 vs. ALRPRB: 8.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALRPRB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -289.92   Max: 66.78
Current: 8.26

-289.92
66.78
Revenue Growth (3Y)(%) 2.80
ALRPRB's Revenue Growth (3Y)(%) is ranked lower than
65% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. ALRPRB: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALRPRB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -8.6   Max: 36.2
Current: 2.8

-8.6
36.2
EBITDA Growth (3Y)(%) -0.10
ALRPRB's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ALRPRB: -0.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALRPRB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.3   Max: 103.3
Current: -0.1

-9.3
103.3
EPS Growth (3Y)(%) 14.60
ALRPRB's EPS Growth (3Y)(%) is ranked higher than
77% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. ALRPRB: 14.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALRPRB' s 10-Year EPS Growth (3Y)(%) Range
Min: -57.6   Max: 75.3
Current: 14.6

-57.6
75.3
» ALRPRB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ALRPRB Guru Trades in Q2 2014

Pioneer Investments 127,839 sh (unchged)
Howard Marks 212,800 sh (unchged)
Private Capital 5,337 sh (-0.09%)
» More
Q3 2014

ALRPRB Guru Trades in Q3 2014

Pioneer Investments 95,085 sh (unchged)
Private Capital 5,187 sh (-2.81%)
Howard Marks 83,368 sh (-60.82%)
» More
Q4 2014

ALRPRB Guru Trades in Q4 2014

Howard Marks 100,733 sh (+20.83%)
Pioneer Investments 95,085 sh (unchged)
Private Capital 5,142 sh (-0.87%)
» More
Q1 2015

ALRPRB Guru Trades in Q1 2015

Howard Marks 107,733 sh (+6.95%)
Private Capital 5,142 sh (unchged)
Pioneer Investments 37,314 sh (-60.76%)
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB15.423.44

Ratios

vs
industry
vs
history
P/E(ttm) 29.20
ALRPRB's P/E(ttm) is ranked higher than
59% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. ALRPRB: 29.20 )
Ranked among companies with meaningful P/E(ttm) only.
ALRPRB' s 10-Year P/E(ttm) Range
Min: 26.09   Max: 3605
Current: 29.2

26.09
3605
Forward P/E 18.83
ALRPRB's Forward P/E is ranked lower than
52% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.57 vs. ALRPRB: 18.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.98
ALRPRB's P/B is ranked higher than
55% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ALRPRB: 2.98 )
Ranked among companies with meaningful P/B only.
ALRPRB' s 10-Year P/B Range
Min: 0.42   Max: 2.98
Current: 2.98

0.42
2.98
P/S 1.62
ALRPRB's P/S is ranked higher than
71% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ALRPRB: 1.62 )
Ranked among companies with meaningful P/S only.
ALRPRB' s 10-Year P/S Range
Min: 0.52   Max: 4.12
Current: 1.62

0.52
4.12
PFCF 81.87
ALRPRB's PFCF is ranked lower than
92% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.00 vs. ALRPRB: 81.87 )
Ranked among companies with meaningful PFCF only.
ALRPRB' s 10-Year PFCF Range
Min: 8.97   Max: 135.97
Current: 81.87

8.97
135.97
POCF 27.88
ALRPRB's POCF is ranked lower than
69% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.74 vs. ALRPRB: 27.88 )
Ranked among companies with meaningful POCF only.
ALRPRB' s 10-Year POCF Range
Min: 4.63   Max: 132.61
Current: 27.88

4.63
132.61
EV-to-EBIT 94.81
ALRPRB's EV-to-EBIT is ranked lower than
93% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.53 vs. ALRPRB: 94.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ALRPRB' s 10-Year EV-to-EBIT Range
Min: -884.5   Max: 2833.4
Current: 94.81

-884.5
2833.4
Current Ratio 2.18
ALRPRB's Current Ratio is ranked lower than
60% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. ALRPRB: 2.18 )
Ranked among companies with meaningful Current Ratio only.
ALRPRB' s 10-Year Current Ratio Range
Min: 0.7   Max: 3.42
Current: 2.18

0.7
3.42
Quick Ratio 1.61
ALRPRB's Quick Ratio is ranked lower than
65% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.35 vs. ALRPRB: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
ALRPRB' s 10-Year Quick Ratio Range
Min: 0.46   Max: 2.89
Current: 1.61

0.46
2.89
Days Inventory 94.54
ALRPRB's Days Inventory is ranked lower than
60% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.12 vs. ALRPRB: 94.54 )
Ranked among companies with meaningful Days Inventory only.
ALRPRB' s 10-Year Days Inventory Range
Min: 38.42   Max: 130.6
Current: 94.54

38.42
130.6
Days Sales Outstanding 64.67
ALRPRB's Days Sales Outstanding is ranked higher than
51% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.92 vs. ALRPRB: 64.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALRPRB' s 10-Year Days Sales Outstanding Range
Min: 51.97   Max: 166.61
Current: 64.67

51.97
166.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.43
ALRPRB's Dividend Yield is ranked lower than
236% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. ALRPRB: 3.43 )
Ranked among companies with meaningful Dividend Yield only.
ALRPRB' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 3.43

Yield on cost (5-Year) 3.43
ALRPRB's Yield on cost (5-Year) is ranked lower than
87% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. ALRPRB: 3.43 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALRPRB' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 3.43

Share Buyback Rate 0.10
ALRPRB's Share Buyback Rate is ranked higher than
79% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.50 vs. ALRPRB: 0.10 )
Ranked among companies with meaningful Share Buyback Rate only.
ALRPRB' s 10-Year Share Buyback Rate Range
Min: 19.3   Max: -54.7
Current: 0.1

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 1.10
ALRPRB's Earnings Yield (Greenblatt) is ranked higher than
53% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.10 vs. ALRPRB: 1.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ALRPRB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 3
Current: 1.1

0.3
3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:IM5.Germany,
Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting innovative diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a strong commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to better manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcome

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK